T cell-based immunity not only plays an important role in tumor diseases, but is also crucial for the defense against viral infections. During the COVID-19 pandemic, we decided to leverage our experience and expertise in tumor immunology to contribute to this field as well. After pioneering preclinical contributions to the understanding of the SARS-CoV-2 T cell response, we developed the T cell activator CoVac-1 with the goal of inducing a protective T cell response in tumor patients and other immunocompromised patients at high risk for a severe COVID-19 course. In a first phase I study in healthy volunteers, CoVac-1 was evaluated with highly encouraging data regarding safety and immunogenicity (NCT04546841). Based on this, CoVac-1 is currently being investigated in a phase II study in patients with congenital and acquired immunodeficiencies with the goal of providing effective protection against severe COVID-19 in this high-risk patient population in the future.
Peptide-based Immunotherapy
frontend.sr-only_#{element.icon}:
Otfried-Müller-Str. 10, 72076 Tübingen
frontend.sr-only_#{element.icon}:
Auf der Morgenstelle 15, 72076 Tübingen
Office:
frontend.sr-only_#{element.icon}:
+49 7071 29-82834
frontend.sr-only_#{element.icon}:
+49 7071 29-4391
frontend.sr-only_#{element.icon}:
PBI@med.uni-tuebingen.de
